Indications and uses
temporarily relieves minor aches and pains due to: • minor pain of arthritis • muscular aches • backache • menstrual cramps • headache • toothache • the common cold temporarily reduces fever
temporarily relieves minor aches and pains due to: • minor pain of arthritis • muscular aches • backache • menstrual cramps • headache • toothache • the common cold temporarily reduces fever
For Tablets: • do not take more than directed • the smallest effective dose should be used • drink a full glass of water with each dose Adults and children 12 years and older • take 1 tablet every 8 to 12 hours while symptoms last • for the first dose you may take 2 tablets within the first hour • do not exceed 2 tablets in any 8- to 12-hour period • do not exceed 3 tablets in a 24-hour period Children und...
For Tablets: • each tablet contains: sodium 20 mg • store at 20-25ºC (68-77ºF). • avoid high humidity and excessive heat above 40°C (104°F). For Caplets: • each caplet contains: sodium 20 mg • store at 20-25ºC (68-77ºF). • avoid high humidity and excessive heat above 40°C (104°F).
For Tablets:
Active ingredient (in each tablet)
Naproxen sodium 220 mg
(naproxen 200 mg) (NSAID)*
*nonsteroidal anti-inflammatory drug
For Caplets:
Active ingredient (in each caplet)
Naproxen sodium 220 mg
(naproxen 200 mg) (NSAID)*
*nonsteroidal anti-inflammatory drug
Pain reliever/ fever reducer
temporarily relieves minor aches and pains due to:
• minor pain of arthritis
• muscular aches
• backache
• menstrual cramps
• headache
• toothache
• the common cold
temporarily reduces fever
Allergy alert: Naproxen sodium may cause a severe allergic reaction, especially in people allergic to aspirin. Symptoms may include:
• hives
• facial swelling
• asthma (wheezing)
• shock
• skin reddening
• rash
• blisters
If an allergic reaction occurs, stop use and seek medical help right away.
Stomach bleeding warning: This product contains an NSAID, which may cause severe stomach bleeding.
The chance is higher if you:
• are age 60 or older
• have had stomach ulcers or bleeding problems
• take a blood thinning (anticoagulant) or steroid drug
• take other drugs containing prescription or nonprescription NSAIDs (aspirin, ibuprofen, naproxen, or others)
• have 3 or more alcoholic drinks every day while using this product
• take more or for a longer time than directed
Heart attack and stroke warning: NSAIDs, except aspirin, increase the risk of heart attack, heart failure, and stroke. These can be fatal. The risk is higher if you use more than directed or for longer than directed.
• if you have ever had an allergic reaction to any other pain reliever/fever reducer
• right before or after heart surgery
• the stomach bleeding warning applies to you
• you have a history of stomach problems, such as heartburn
• you have high blood pressure, heart disease, liver cirrhosis, kidney disease, asthma, or had a stroke
• you are taking a diuretic
• you have problems or serious side effects from taking pain relievers or fever reducers
• under a doctor's care for any serious condition
• taking aspirin for heart attack or stroke, because naproxen may decrease this benefit of aspirin
• taking any other drug
• take with food or milk if stomach upset occurs
you experience any of the following signs of stomach bleeding:
• feel faint
• vomit blood
• have bloody or black stools
• have stomach pain that does not get better
you have symptoms of heart problems or stroke:
• chest pain
• trouble breathing
• weakness in one part or side of body
• slurred speech
• leg swelling
pain gets worse or lasts more than 10 days
fever gets worse or lasts more than 3 days
you have difficulty swallowing
it feels like the pill is stuck in your throat
redness or swelling is present in the painful area
any new symptoms appear
ask a health professional before use. It is especially important not to use naproxen sodium at 20 weeks or later in pregnancy unless definitely directed to do so by a doctor because it may cause problems in the unborn child or complications during delivery.
In case of overdose, get medical help or contact a Poison Control Center right away. (1-800-222-1222)
For Tablets:
• do not take more than directed
• the smallest effective dose should be used
• drink a full glass of water with each dose
| Adults and children 12 years and older | • take 1 tablet every 8 to 12 hours while symptoms last • for the first dose you may take 2 tablets within the first hour • do not exceed 2 tablets in any 8- to 12-hour period • do not exceed 3 tablets in a 24-hour period |
| Children under 12 years | • ask a doctor |
For Caplets:
• do not take more than directed
• the smallest effective dose should be used
• drink a full glass of water with each dose
| Adults and children 12 years and older | • take 1 caplet every 8 to 12 hours while symptoms last • for the first dose you may take 2 caplets within the first hour • do not exceed 2 caplets in any 8- to 12-hour period • do not exceed 3 caplets in a 24-hour period |
| Children under 12 years | • ask a doctor |
For Tablets:
• each tablet contains: sodium 20 mg
• store at 20-25ºC (68-77ºF).
• avoid high humidity and excessive heat above 40°C (104°F).
For Caplets:
• each caplet contains: sodium 20 mg
• store at 20-25ºC (68-77ºF).
• avoid high humidity and excessive heat above 40°C (104°F).
colloidal silicon dioxide, croscarmellose sodium, FD&C blue #2 Lake, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, povidone, titanium dioxide
call toll free 1-877-376-4271
Manufactured for:
Time-Cap Labs, Inc.
7 Michael Avenue, Farmingdale,
NY 11735, USA
Manufactured by:
Marksans Pharma Ltd.
Plot No. L-82, L-83,
Verna Indl. Estate,
Verna, Goa - 403722, India.
Mfg. Lic. No.: GO/DRUGS/515
NDC 25000-141-43
Naproxen Sodium Tablets, USP 220 mg
10’s count bottle label

NDC 25000-141-43
Naproxen Sodium Tablets, USP 220 mg
10’s count carton label
NDC 25000-141-02
Naproxen Sodium Tablets, USP 220 mg
24’s count bottle label
NDC 25000-141-02
Naproxen Sodium Tablets, USP 220 mg
24’s count carton label
NDC 25000-141-14
Naproxen Sodium Tablets, USP 220 mg
1000’s count bottle label
NDC 25000-144-14
Naproxen Sodium Tablets, USP 220 mg (Capsule-shaped tablet)
1000’s count bottle label

NDC 25000-144-43
Naproxen Sodium Tablets, USP 220 mg (Capsule-shaped tablet)
10’s count bottle label
NDC 25000-144-43
Naproxen Sodium Tablets, USP 220 mg (Capsule-shaped tablet)
10’s count carton label

NDC 25000-144-02
Naproxen Sodium Tablets, USP 220 mg (Capsule-shaped tablet)
24’s count bottle label
NDC 25000-144-02
Naproxen Sodium Tablets, USP 220 mg (Capsule-shaped tablet)
24’s count carton label
| Class | Version | Type | Effective |
|---|---|---|---|
| NAPROXEN Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20191108 |
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| fef6ad89-235f-4274-ba49-a8e53642473e | Product name | 2 | 20250225 |
| 87fed3e6-8fba-48ef-96b0-3a7fb54b96ff | Product name | 3 | 20230306 |
| b5fdaaec-7251-4da6-9cb2-4e9e76939ec8 | Product name | 1 | 20200623 |
| e76dbbc1-775d-722c-08ff-ed45e8a80def | Product name | 3 | 20181002 |
| 6f4f4521-fd56-1ae6-888b-3b021bd75c7c | Product name | 1 | 20140508 |
| ce67e27d-1d21-5465-4409-b0662dd99d4d | Product name | 1 | 20140508 |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 25000-141-02 | Naproxen Sodium | 1 in 1 CARTON | TABLET | 1 | 8 | |
| 25000-141-02 | Naproxen Sodium | 160 in 1 BOX | TABLET | 160 | 8 | |
| 25000-141-14 | Naproxen Sodium | 1000 in 1 BOTTLE, PLASTIC | TABLET | 1000 | 8 | |
| 25000-141-26 | Naproxen Sodium | 2 in 1 BOX | TABLET | 2 | 8 | |
| 25000-141-26 | Naproxen Sodium | 1600 in 1 BAG | TABLET | 1600 | 8 | |
| 25000-141-30 | Naproxen Sodium | 6500 in 1 BAG | TABLET | 6500 | 8 | |
| 25000-141-30 | Naproxen Sodium | 6 in 1 BOX | TABLET | 6 | 8 | |
| 25000-141-43 | Naproxen Sodium | 10 in 1 BOTTLE | TABLET | 10 | 8 | |
| 25000-141-98 | Naproxen Sodium | 1 in 1 BOX | TABLET | 1 | 8 | |
| 25000-141-98 | Naproxen Sodium | 32165 in 1 BAG | TABLET | 32165 | 8 | |
| 25000-144-02 | Naproxen Sodium | 1 in 1 CARTON | TABLET | 1 | 8 | |
| 25000-144-02 | Naproxen Sodium | 160 in 1 BOX | TABLET | 160 | 8 | |
| 25000-144-14 | Naproxen Sodium | 1000 in 1 BOTTLE, PLASTIC | TABLET | 1000 | 8 | |
| 25000-144-20 | Naproxen Sodium | 4 in 1 BOX | TABLET | 4 | 8 | |
| 25000-144-20 | Naproxen Sodium | 6500 in 1 BAG | TABLET | 6500 | 8 | |
| 25000-144-30 | Naproxen Sodium | 6 in 1 BOX | TABLET | 6 | 8 | |
| 25000-144-30 | Naproxen Sodium | 6500 in 1 BAG | TABLET | 6500 | 8 | |
| 25000-144-43 | Naproxen Sodium | 10 in 1 BOTTLE | TABLET | 10 | 8 | |
| 25000-144-98 | Naproxen Sodium | 1 in 1 BOX | TABLET | 1 | 8 | |
| 25000-144-98 | Naproxen Sodium | 32165 in 1 BAG | TABLET | 32165 | 8 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 25000-141 | NAPROXEN SODIUM (NAPROXEN SODIUM TABLET, COATED) TABLET NAPROXEN SODIUM (NAPROXEN SODIUM, COATED TABLETS) TABLET [MARKSANS PHARMA LIMITED] | 8 | Current NDC, Legacy NDC, 10 package rows | 20230615_48cb1363-ff12-40ee-a87a-2252dfbf8ff7.zip |
| 25000-144 | NAPROXEN SODIUM (NAPROXEN SODIUM TABLET, COATED) TABLET NAPROXEN SODIUM (NAPROXEN SODIUM, COATED TABLETS) TABLET [MARKSANS PHARMA LIMITED] | 8 | Current NDC, Legacy NDC, 10 package rows | 20230615_48cb1363-ff12-40ee-a87a-2252dfbf8ff7.zip |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| NAPROXEN SODIUM | ACTIVE INGREDIENT | 9TN87S3A3C | 3 | |
| NAPROXEN | ACTIVE MOIETY | 57Y76R9ATQ | 3 | |
| CELLULOSE, MICROCRYSTALLINE | INACTIVE INGREDIENT | OP1R32D61U | 3 | |
| COLLOIDAL SILICON DIOXIDE | INACTIVE INGREDIENT | ETJ7Z6XBU4 | 3 | |
| CROSCARMELLOSE SODIUM | INACTIVE INGREDIENT | M28OL1HH48 | 3 | |
| FD&C BLUE NO. 2 | INACTIVE INGREDIENT | L06K8R7DQK | 3 | |
| HYPROMELLOSES | INACTIVE INGREDIENT | 3NXW29V3WO | 3 | |
| MAGNESIUM STEARATE | INACTIVE INGREDIENT | 70097M6I30 | 3 | |
| POLYETHYLENE GLYCOL | INACTIVE INGREDIENT | 3WJQ0SDW1A | 3 | |
| POVIDONE | INACTIVE INGREDIENT | FZ989GH94E | 3 | |
| TITANIUM DIOXIDE | INACTIVE INGREDIENT | 15FIX9V2JP | 3 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 25000-141 | 25000-141-14, 25000-141-26, 25000-141-30, 25000-141-02, 25000-141-43, 25000-141-98 |
| 25000-144 | 25000-144-14, 25000-144-20, 25000-144-30, 25000-144-02, 25000-144-43, 25000-144-98 |
Every source-derived ingredient row is available through these pages.
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| HYPROMELLOSES | HYPROMELLOSE | 3NXW29V3WO | TABLET / ORAL | 1127 mg | ||
| HYPROMELLOSES | HYPROMELLOSE | 3NXW29V3WO | TABLET / ORAL | 1127 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET / ORAL | 232 mg | ||
| POVIDONE | POVIDONE | FZ989GH94E | TABLET / ORAL | 216 mg | ||
| HYPROMELLOSES | HYPROMELLOSE | 3NXW29V3WO | TABLET / ORAL | 1127 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET / ORAL | 980 mg | ||
| POVIDONE | POVIDONE | FZ989GH94E | TABLET / ORAL | 216 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET / ORAL | 980 mg | ||
| COLLOIDAL SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET / ORAL | 750 mg | ||
| CROSCARMELLOSE SODIUM | CROSCARMELLOSE SODIUM | M28OL1HH48 | TABLET / ORAL | 736 mg | ||
| POVIDONE | POVIDONE | FZ989GH94E | TABLET / ORAL | 216 mg | ||
| FD&C BLUE NO. 2 | FD&C BLUE NO. 2 | L06K8R7DQK | TABLET / ORAL | 25 mg | ||
| FD&C BLUE NO. 2 | FD&C BLUE NO. 2 | L06K8R7DQK | TABLET / ORAL | 25 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET / ORAL | 232 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET / ORAL | 980 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET / ORAL | 6184 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET / ORAL | 6184 mg | ||
| HYPROMELLOSES | HYPROMELLOSE | 3NXW29V3WO | TABLET / ORAL | 1127 mg | ||
| COLLOIDAL SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET / ORAL | 750 mg | ||
| COLLOIDAL SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET / ORAL | 750 mg | ||
| CROSCARMELLOSE SODIUM | CROSCARMELLOSE SODIUM | M28OL1HH48 | TABLET / ORAL | 736 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET / ORAL | 980 mg | ||
| HYPROMELLOSES | HYPROMELLOSE | 3NXW29V3WO | TABLET / ORAL | 1127 mg | ||
| HYPROMELLOSES | HYPROMELLOSE | 3NXW29V3WO | TABLET / ORAL | 1127 mg | ||
| CROSCARMELLOSE SODIUM | CROSCARMELLOSE SODIUM | M28OL1HH48 | TABLET / ORAL | 736 mg | ||
| COLLOIDAL SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET / ORAL | 750 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET / ORAL | 6184 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET / ORAL | 980 mg | ||
| FD&C BLUE NO. 2 | FD&C BLUE NO. 2 | L06K8R7DQK | TABLET / ORAL | 25 mg | ||
| POVIDONE | POVIDONE | FZ989GH94E | TABLET / ORAL | 216 mg | ||
| HYPROMELLOSES | HYPROMELLOSE | 3NXW29V3WO | TABLET / ORAL | 1127 mg | ||
| FD&C BLUE NO. 2 | FD&C BLUE NO. 2 | L06K8R7DQK | TABLET / ORAL | 25 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET / ORAL | 232 mg | ||
| HYPROMELLOSES | HYPROMELLOSE | 3NXW29V3WO | TABLET / ORAL | 1127 mg | ||
| FD&C BLUE NO. 2 | FD&C BLUE NO. 2 | L06K8R7DQK | TABLET / ORAL | 25 mg | ||
| CROSCARMELLOSE SODIUM | CROSCARMELLOSE SODIUM | M28OL1HH48 | TABLET / ORAL | 736 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET / ORAL | 232 mg | ||
| POVIDONE | POVIDONE | FZ989GH94E | TABLET / ORAL | 216 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET / ORAL | 980 mg | ||
| FD&C BLUE NO. 2 | FD&C BLUE NO. 2 | L06K8R7DQK | TABLET / ORAL | 25 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET / ORAL | 232 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET / ORAL | 6184 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET / ORAL | 6184 mg | ||
| POVIDONE | POVIDONE | FZ989GH94E | TABLET / ORAL | 216 mg | ||
| POVIDONE | POVIDONE | FZ989GH94E | TABLET / ORAL | 216 mg | ||
| CROSCARMELLOSE SODIUM | CROSCARMELLOSE SODIUM | M28OL1HH48 | TABLET / ORAL | 736 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET / ORAL | 980 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET / ORAL | 6184 mg | ||
| HYPROMELLOSES | HYPROMELLOSE | 3NXW29V3WO | TABLET / ORAL | 1127 mg | ||
| HYPROMELLOSES | HYPROMELLOSE | 3NXW29V3WO | TABLET / ORAL | 1127 mg | ||
| COLLOIDAL SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET / ORAL | 750 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET / ORAL | 6184 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET / ORAL | 980 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET / ORAL | 6184 mg | ||
| CROSCARMELLOSE SODIUM | CROSCARMELLOSE SODIUM | M28OL1HH48 | TABLET / ORAL | 736 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET / ORAL | 232 mg | ||
| HYPROMELLOSES | HYPROMELLOSE | 3NXW29V3WO | TABLET / ORAL | 1127 mg | ||
| FD&C BLUE NO. 2 | FD&C BLUE NO. 2 | L06K8R7DQK | TABLET / ORAL | 25 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET / ORAL | 6184 mg | ||
| HYPROMELLOSES | HYPROMELLOSE | 3NXW29V3WO | TABLET / ORAL | 1127 mg |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A090545-001 | NAPROXEN SODIUM | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 2011-03-16 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A090545-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 2011-03-16 | 84e616aacf4f… | ||
| 2026-08-18 06:07:40 | 2026-07 | A090545-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 2011-03-16 | caaa826d4ba7… | ||
| 2026-02-19 14:30 UTC | 2026-02 | A090545-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 2011-03-16 | 011fe1cb6892… | ||
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A090545-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 2011-03-16 | 31067a03dcf5… | ||
| 2025-08-23 18:47 UTC | 2025-08 | A090545-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 2011-03-16 | 6a471c1ec25d… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A090545-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 2011-03-16 | fd3edfee7708… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A090545-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 2011-03-16 | b8a1b40f171c… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A090545-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 2011-03-16 | 03ed91905a0d… | ||
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A090545-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 2011-03-16 | 2680178bc6a6… | ||
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A090545-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 2011-03-16 | 5bbf6a4d5a75… | ||
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A090545-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 2011-03-16 | d8e5a09893c0… | ||
| 2024-10-29 15:01 UTC | 2024-10 | A090545-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 2011-03-16 | d06236e962d9… | ||
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A090545-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 2011-03-16 | 79d66fd596c7… | ||
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A090545-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 2011-03-16 | 301d65b070ca… | ||
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A090545-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 2011-03-16 | 1e350fbaab3a… | ||
| 2024-05-31 18:47 UTC | 2024-05 | A090545-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 2011-03-16 | 8072bd15b7f6… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A090545-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 2011-03-16 | 5c6f7cd8ea54… | ||
| 2022-04-08 23:34 UTC | 2022-04 | A090545-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 2011-03-16 | 5d02ea3f76ae… | ||
| 2022-04-04 05:41 UTC | 2022-04 | A090545-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 2011-03-16 | 4b0b4de00fa7… | ||
| 2019-12-13 00:20 UTC | 2019-12 | A090545-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 2011-03-16 | 74a2ff9319b5… | ||
| 2022-03-09 01:35 UTC | 2022-03 | A090545-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 2011-03-16 | bb7c543d1eb4… | ||
| 2021-12-28 21:50 UTC | 2021-12 | A090545-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 2011-03-16 | 782e0a99824c… | ||
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A090545-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 2011-03-16 | 87673890dc5c… | ||
| 2021-03-12 10:30 UTC | 2021-03 | A090545-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 2011-03-16 | 5aa47cf7b7d7… | ||
| 2020-12-22 03:56 UTC | 2020-12 | A090545-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 2011-03-16 | 8869cabd3fbd… | ||
| 2020-11-12 02:37 UTC | 2020-11 | A090545-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 2011-03-16 | c0c555d07b60… | ||
| 2019-12-14 00:12 UTC | 2019-12 | A090545-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 2011-03-16 | 3f01610625f2… | ||
| 2019-09-15 20:21 UTC | 2019-09 | A090545-001 | NAPROXEN SODIUM | EQ 200MG BASE | TABLET / ORAL | 2011-03-16 | b00525d2431f… | ||
| 2019-07-19 19:46 UTC | 2019-07 | A090545-001 | NAPROXEN SODIUM | EQ 200MG BASE | TABLET / ORAL | 2011-03-16 | ea99ee380514… | ||
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A090545-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 2011-03-16 | 6a51e52b5d6a… | ||
| 2024-02-18 07:12 UTC | 2024-02 | A090545-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 2011-03-16 | 1c564ffb4f44… | ||
| 2023-12-20 04:57 UTC | 2023-12 | A090545-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 2011-03-16 | ea1830bbd6c7… | ||
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A090545-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 2011-03-16 | a72a2bbeb626… | ||
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A090545-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 2011-03-16 | 9b2671bbb829… | ||
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A090545-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 2011-03-16 | a67488948f0b… | ||
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A090545-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 2011-03-16 | 3f0d92c62455… | ||
| 2023-05-13 08:27 UTC | 2023-05 | A090545-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 2011-03-16 | 053a50430f4f… | ||
| 2023-01-26 05:58 UTC | 2023-01 | A090545-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 2011-03-16 | 3bdfa0b2c4d7… | ||
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A090545-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 2011-03-16 | 3a93d1ddd44b… | ||
| 2022-10-28 04:53 UTC | 2022-10 | A090545-001 | NAPROXEN SODIUM | 220MG | TABLET / ORAL | 2011-03-16 | f41ea6bd6efb… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Naproxen Sodium | NAPROXEN SODIUM, COATED TABLETS | MARKSANS PHARMA LIMITED | 48cb1363-ff12-40ee-a87a-2252dfbf8ff7 | 2023-06-09 | Warnings | 25000-141-30 25000-141-02 25000-141-43 25000-144-20 25000-144-43 25000-141-14 25000-144-14 25000-144-02 25000-141-98 25000-144-98 25000-141-26 25000-144-30 25000-144 25000-141 25000014430 25000014414 25000014443 25000014420 25000014114 25000014402 25000014130 25000014126 25000014102 25000014198 25000014498 25000014143 1e0b6883-f02c-4259-b905-9716dd72bcbf 48cb1363-ff12-40ee-a87a-2252dfbf8ff7 |
Adverse event summaries are temporarily unavailable. Other product information remains available.